Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Zacks11-08

Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481193954?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a","is_english":true,"pubTime":"2024-11-08 07:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481193954","market":"us","top_or_hot":-1,"title":"Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings","media":"Zacks","content":"<div>\n<p>Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-key-metrics-tell-us-233010311.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-key-metrics-tell-us-233010311.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-key-metrics-tell-us-233010311.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COLL","symbol_name":"Collegium Pharmaceutical, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-key-metrics-tell-us-233010311.html","article_id":"2481193954","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481193954","pubTimestamp":1731022210,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Collegium Pharmaceutical  reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $1.34 a year ago.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $159.99 million. With the consensus EPS estimate being $1.66, the EPS surprise was -3.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Total product revenues- Nucynta: $45.13 million versus $43.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change.Total product revenues- Xtam","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"COLL":"Collegium Pharmaceutical, Inc."},"translate_title":"以下是有关Collegium Pharmaceutical(COLL)第三季度收益的关键指标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COLL":1},"content_text":"Collegium Pharmaceutical (COLL) reported $159.3 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 16.5%. EPS of $1.61 for the same period compares to $1.34 a year ago.\nThe reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $159.99 million. With the consensus EPS estimate being $1.66, the EPS surprise was -3.01%.\nWhile investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.\nAs these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.\nHere is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nTotal product revenues- Belbuca: $53.20 million compared to the $52.53 million average estimate based on three analysts. The reported number represents a change of +17.1% year over year.\nTotal product revenues- Nucynta: $45.13 million versus $43.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change.\nTotal product revenues- Symproic: $3.57 million compared to the $3.77 million average estimate based on three analysts. The reported number represents a change of -9% year over year.\nTotal product revenues- Xtampza ER: $49.49 million versus $47.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +24.4% change.\n View all Key Company Metrics for Collegium Pharmaceutical here>>>\n\nShares of Collegium Pharmaceutical have returned -8.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCollegium Pharmaceutical, Inc. (COLL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481193954"}